Here's a review of the headline numbers from the company's report:
- Revenue jumped 8% to $1.08 billion. The growth was driven by acquisitions, new drug launches, and manufacturer price increases. However, those gains were offset by contract losses and falling sales of hepatitis C drugs such as Gilead Sciences' (GILD 1.29%) Sovaldi and Harvoni. The top-line result came in a hair below what Wall Street was looking for.
- Net income from operations plunged 72% to $4.23 million. The drop was blamed on higher direct and indirect remuneration (DIR) fees, product mix, and higher expenses.
- On an adjusted basis, earnings per share declined by 17% to $0.19. That result was well ahead of the $0.15 in adjusted EPS that market watchers were projecting.
Management also reaffirmed its full-year guidance, which calls for revenue to land between $4.3 billion and $4.7 billion and adjusted EPS to come in between $0.54 and $0.70.
The market responded positively to the news of better-than-expected adjusted profits, which is why shares moved higher in afternoon trading.
While DIR fees remain a thorn in Diplomat's side, there are reasons to believe that positive changes could be on the way. Legislators on both sides of the political aisle have expressed an interest in prohibiting these fees. If DIR fees are eventually removed, it is likely that Diplomat's profits would get a substantial boost.
There are also reasons to believe that the worst of the declines in hepatitis C sales might be nearing an end. Gilead Sciences recently reported a small drop-off in U.S. patient starts, quarter over quarter, and they also reaffirmed full-year revenue guidance.
Overall, Diplomat's near-term results continue to look murky, but there are reasons to believe that the company could soon return to growing the bottom line. If true, that would be welcome news to the bulls who have stuck with it through this challenging period.